Source: European Medicines Agency (EU) Revision Year: 2020 Publisher: Ipsen Pharma, 65 quai Georges Gorse, 92100, Boulogne-Billancourt, France
CABOMETYX 20 mg film-coated tablets.
CABOMETYX 40 mg film-coated tablets.
CABOMETYX 60 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. CABOMETYX 20 mg film-coated tablets: The tablets are yellow round with no score, and debossed with “XL” on one side and “20” on the other side of the tablet. CABOMETYX 40 mg film-coated tablets: The tablets are yellow triangle shaped with no score, and debossed with “XL” on one side and “40” on the other side of the tablet. CABOMETYX 60 mg film-coated tablets: The tablets are yellow oval shaped with no score, and debossed with “XL” on one side and “60” on the other side of the tablet. |
CABOMETYX 20 mg film-coated tablets: Each film-coated tablet contains cabozantinib (S)-malate equivalent to 20 mg cabozantinib.
Excipients with known effect: Each film-coated tablet contains 15.54 mg lactose.
CABOMETYX 40 mg film-coated tablets: Each film-coated tablet contains cabozantinib (S)-malate equivalent to 40 mg cabozantinib.
Excipients with known effect: Each film-coated tablet contains 31.07 mg lactose.
CABOMETYX 60 mg film-coated tablets: Each film-coated tablet contains cabozantinib (S)-malate equivalent to 60 mg cabozantinib.
Excipients with known effect: Each film-coated tablet contains 46.61 mg lactose.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Cabozantinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumour growth and angiogenesis, pathologic bone remodeling, drug resistance, and metastatic progression of cancer. Cabozantinib was evaluated for its inhibitory activity against a variety of kinases and was identified as an inhibitor of MET (hepatocyte growth factor receptor protein) and VEGF (vascular endothelial growth factor) receptors. In addition, cabozantinib inhibits other tyrosine kinases including the GAS6 receptor (AXL), RET, ROS1, TYRO3, MER, the stem cell factor receptor (KIT), TRKB, Fms-like tyrosine kinase-3 (FLT3), and TIE-2. |
| List of Excipients |
|---|
|
Tablet content: Microcrystalline cellulose Film-coating: Hypromellose 2910 |
PVC/PCTFE blister with push-through aluminum foil backing containing 7 film-coated tablets. Each carton contains 4 blisters with 28 film-coated tablets.
HDPE bottle with a polypropylene child-resistant closure and three silica gel dessicant canisters. Each bottle contains 30 film-coated tablets.
Not all pack sizes may be marketed.
Ipsen Pharma, 65 quai Georges Gorse, 92100, Boulogne-Billancourt, France
Cabometyx 20 mg film-coated tablets:
EU/1/16/1136/001
EU/1/16/1136/002
Cabometyx 40 mg film-coated tablets:
EU/1/16/1136/003
EU/1/16/1136/004
Cabometyx 60 mg film-coated tablets:
EU/1/16/1136/005
EU/1/16/1136/006
Date of first authorisation: 09 September 2016
| Drug | Countries | |
|---|---|---|
| CABOMETYX | Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.